Posted by Michael Wonder on 25 Aug 2024
Padcev (enfortumab vedotin) in combination with pembrolizumab approved by Health Canada to treat advanced bladder cancer
22 August 2024 - Padcev plus pembrolizumab approved based on EV-302 trial.
Pfizer Canada today announced that Health Canada has approved Padcev (enfortumab vedotin) an antibody-drug conjugate in combination with pembrolizumab, a PD-1 inhibitor, for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer with no prior systemic therapy for metastatic urothelial cancer.
